GILD — Gilead Sciences
Price when we picked it (Jun 11, 2026)
$121.79
Target: $160.00 (+23.2%)
P/E Ratio
19.1
P/E Forward
13.5
Dividend
2.52%
Market Cap
$161.1B
EPS
$6.78
Consensus
Strong Buy
What they do
Gilead Sciences (NASDAQ: GILD) is a biotech pharma company and the global leader in treating HIV (the virus that causes AIDS), headquartered in Foster City, California.
How it makes money: it sells prescription medicines, mostly for HIV. Its franchises:
1. HIV — the heart of the business (~$5 billion per quarter): its Biktarvy pill is the #1 HIV treatment in the U.S. (over 52% share) and sells ~$3.4 billion a quarter. Descovy is for prevention.
2. HIV prevention — the new catalyst: Yeztugo (lenacapavir), a long-acting shot given just twice a year to prevent infection.
3. Oncology (cancer): Trodelvy (breast cancer) and CAR-T cell therapies through its Kite unit.
4. Liver and others: hepatitis B/C/D and Veklury (the COVID antiviral).
Leadership: CEO Daniel O'Day. HQ Foster City, California.
Q1 2026: revenue ~$7 billion (+4%), HIV sales $5 billion (+10%). Yeztugo billed $166 million in the quarter (+72% over the prior one) and Gilead raised its full-year forecast for that drug to ~$1 billion.
Why we like it
GILD at $121.79 is buying the global HIV leader — a huge, stable business — right as it launches a shot that could redefine HIV prevention, while paying ~19x profit with a ~2.69% dividend. Specific reasons:
- HIV dominance: Biktarvy is the #1 pill in the U.S. (>52% share) and generates ~$3.4 billion a quarter — a very predictable river of cash.
- Yeztugo, the catalyst: a twice-a-year shot that prevented HIV with nearly 100% effectiveness in trials; it's already on track for ~$1 billion in its first year and could be a blockbuster for years.
- Diversification: oncology (Trodelvy) and cell therapies (Kite) add growth beyond HIV.
- Rising dividend: it pays ~2.69% and has raised it ~10 years in a row — it pays you rent while you wait.
- Reasonable valuation: ~19x profit (~15x next year's) for a moated franchise with a big launch underway.
- The backdrop: analysts see the stock at ~$159 (~+30%) on average. Analysts: Buy, target ~$159 (~+30%).
Key Risk
Risks:
- Biktarvy dependence — #1: a single drug generates >$13 billion a year; when it loses patent protection, cheap generics will eat its sales. The good news: Gilead reached settlements pushing U.S. generic entry to 2036 — that delays the problem, it doesn't remove it.
- HIV competition: GSK/ViiV (with its Cabenuva/Apretude injectables) and Merck (with islatravir) are going after the same market.
- Yeztugo launch execution: much of the growth thesis depends on the shot selling well — insurance coverage, adoption pace.
- Oncology pipeline: if Trodelvy or Kite's cell therapies disappoint, the diversification weakens.
- Drug-pricing pressure: the IRA law lets Medicare negotiate prices — a regulatory risk to its drugs.
- Binary regulatory risk: it has pending FDA decisions (e.g. Aug 27, 2026) that can swing the stock sharply either way.
This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.
Vectorial Data picked GILD on Apr 27, 2026 at $129.83.
Full Research
Gilead Sciences (GILD) — Full Research
Price: $121.79 | P/E TTM: ~19x | P/E fwd: ~15x | Div Yield: ~2.69% | Market Cap: ~$151.6B USD
What is Gilead?
A biotech pharma company and global leader in HIV. NASDAQ: GILD. HQ Foster City, California. CEO Daniel O'Day.
Franchises
| Area | What it is |
|---|---|
| HIV (core) | Biktarvy (#1 in the U.S., >52% share, ~$3.4B/qtr) + Descovy |
| HIV prevention | Yeztugo (lenacapavir) — twice-a-year shot |
| Oncology | Trodelvy + CAR-T cell therapy via Kite |
| Liver / others | Hepatitis B/C/D, Veklury (COVID) |
The catalyst: Yeztugo (lenacapavir)
- A long-acting shot, just twice a year, to prevent HIV.
- In trials (PURPOSE-1) it prevented HIV with nearly 100% effectiveness — essentially zero infections.
- Q1 2026: $166M (+72% over the prior quarter). Full-year guidance raised to ~$1 billion.
Q1 2026
| Metric | Q1 2026 | YoY |
|---|---|---|
| Revenue | ~$7 billion | +4% |
| HIV sales | $5 billion | +10% |
| Biktarvy | $3.4 billion | +7% |
Dividend
- Yield ~2.69% (~$3.28/share a year).
- ~10 consecutive years of increases (a grower, though NOT an 'Aristocrat' — that needs 25).
Anchor Fact
Gilead launched a shot, Yeztugo (lenacapavir), given just TWICE a year that, in its trials, prevented HIV with nearly 100% effectiveness — essentially zero infections among thousands of participants. Two shots a year instead of a daily pill: it's arguably the most powerful tool ever for stopping HIV transmission, and it's only just starting to sell.
Top Risks
- Biktarvy dependence — >$13B/yr in one drug; generics by ~2036
- HIV competition — GSK/ViiV, Merck (islatravir)
- Yeztugo execution — coverage and adoption pace
- Oncology pipeline — Trodelvy / Kite
- Drug pricing — Medicare negotiation (IRA)
- Binary regulatory risk — FDA decisions (e.g. Aug 27, 2026)
Analyst Consensus
- Rating: Buy
- Average target: ~$159 (~+30% from $121.79)
Thesis in one line
The global HIV leader, with Biktarvy's river of cash and a shot (Yeztugo) that prevents HIV nearly 100% twice a year — growth + a ~2.69% dividend at ~19x profit.
Research date: 11 Jun 2026 | Next review: Dec 2026
This is not financial advice.
This is not financial advice. Consult a certified financial advisor.
The author may hold positions in the securities discussed.
Past performance does not guarantee future results.